Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | MPO | P05164 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19437236 | 0.84 | MPO (0.43) | FFAR1FFAR4PGRKIF11KDM4E | |
| SCHEMBL7770769 | 0.82 | FFAR1 (0.43) | FFAR1FFAR4CTSBNR3C1PGR | |
| SCHEMBL1162443 | 0.80 | FFAR1 (0.45) | FFAR1FFAR4CTSBNR3C1PGR | |
| SCHEMBL14625917 | 0.80 | FFAR1 (0.42) | FFAR1FFAR4CTSBNR3C1PGR | |
| SCHEMBL29946061 | 0.80 | FFAR1 (0.42) | FFAR1FFAR4CTSBNR3C1PGR | |
| SCHEMBL24136215 | 0.80 | FFAR1 (0.45) | FFAR1FFAR4CTSBNR3C1PGR | |
| SCHEMBL5047708 | 0.80 | LOXL2 (0.47) | FFAR1FFAR4CTSBNR3C1PGR | |
| SCHEMBL309991 | 0.80 | FFAR1 (0.42) | FFAR1FFAR4CTSBNR3C1PGR | |
| SCHEMBL1642300 | 0.80 | FFAR1 (0.48) | FFAR1FFAR4CTSBNR3C1PGR | |
| SCHEMBL6942504 | 0.80 | FFAR1 (0.45) | FFAR1FFAR4CTSBNR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007069986-A1 | NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | claimed |
| US-10959432-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2021-03-30 | — | — | US | disclosed |
| US-10757941-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2020-09-01 | — | — | US | disclosed |
| US-20200267986-A1 | Microbiocidal Oxadiazole Derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2020-08-27 | — | — | US | disclosed |
| US-10687533-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2020-06-23 | — | — | US | disclosed |
| EP-3439477-B1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2020-05-06 | — | — | EP | disclosed |
| US-20190274304-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-09-12 | — | — | US | disclosed |
| EP-3487843-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | Syngenta Participations AG (CH) | 2019-05-29 | — | — | EP | disclosed |
| US-20190090486-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-03-28 | — | — | US | disclosed |
| EP-3439477-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | Syngenta Participations AG (CH) | 2019-02-13 | — | — | EP | disclosed |
| WO-2018015447-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2018-01-25 | — | — | WO | disclosed |
| WO-2017174158-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-10-12 | — | — | WO | disclosed |
| WO-2007069986-A1 | NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10959432-B2 | Microbiocidal oxadiazole derivatives | PRF1, NOX1, ARG1 | FFAR1 421/4885FFAR4 998/4885CTSB 831/4885 |
| US-10687533-B2 | Microbiocidal oxadiazole derivatives | PRF1, NOX1, ARG1 | FFAR1 421/4885FFAR4 998/4885CTSB 831/4885 |
| US-10757941-B2 | Microbiocidal oxadiazole derivatives | PRF1, NOX1, ARG1 | FFAR1 440/4885FFAR4 1021/4885CTSB 840/4885 |
| US-20200267986-A1 | Microbiocidal Oxadiazole Derivatives | PRF1, NOX1, ARG1 | FFAR1 421/4885FFAR4 998/4885CTSB 831/4885 |
| US-20190090486-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | PRF1, NOX1, ARG1 | FFAR1 421/4885FFAR4 998/4885CTSB 831/4885 |
| US-20190274304-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | PRF1, NOX1, ARG1 | FFAR1 440/4885FFAR4 1021/4885CTSB 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.